IBIO

SEC source: 0001408408-20-000039 · ownership.xml · nonDerivative · entry 1

Eastern Capital LTD · CIK 0001408408 · 10% owner

Portfolio Services Ltd. · CIK 0001488856 · 10% owner

DART KENNETH BRYAN · CIK 0001331271 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,782,734

F1 · security: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $4.31 to $4.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request.

F1 · price: The Price reported in Column 4 is a weighted average price. This transaction was executed in multiple trades at prices ranging from $4.31 to $4.47. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff, the Issuer or a security holder of the Issuer upon request.

SEC source: 0001104659-20-073831 · tm2022528d1_4.xml · derivative · entry 1

Kay Robert · CIK 0001285612 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2030-06-12

F1 · shares: Immediate vesting as to 50,000 shares of Common Stock underlying the option and the remaining shares vest pro rata on a monthly basis over the next 21 months.

SEC source: 0001104659-20-118870 · tm2034091d1_4.xml · derivative · entry 1

Kay Robert · CIK 0001285612 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2030-06-12

F1 · derivative.exercise_price: This amendment on Form 4/A is being filed to amend the original Form 4 filed by the reporting person on June 16, 2020 (the "Original Form 4") solely to amend the exercise price in Column 2 of Table II which was incorrectly reported in the Original Form 4. All other information in the Original Form 4 remains unchanged.

F2 · shares: Immediate vesting as to 50,000 shares of Common Stock underlying the option and the remaining shares vest pro rata on a monthly basis over the next 21 months.

SEC source: 0001638599-20-000582 · doc4_6747.xml · derivative · entry 3

ERWIN ROBERT L · CIK 0001213822 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,108

Underlying: Common Stock · 28,268 shares

Expires 2024-02-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of option grants to the reporting person in exchange for the options exercised in the transactions reported on this Form 4.

F1 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-20-000582 · doc4_6747.xml · nonDerivative · entry 2

ERWIN ROBERT L · CIK 0001213822 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,108

F1 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-20-000582 · doc4_6747.xml · nonDerivative · entry 1

ERWIN ROBERT L · CIK 0001213822 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,108

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-20-000552 · doc4_6734.xml · derivative · entry 3

ERWIN ROBERT L · CIK 0001213822 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,376

Underlying: Common Stock · 96,124 shares

Expires 2024-02-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options.

F1 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-20-000552 · doc4_6734.xml · nonDerivative · entry 2

ERWIN ROBERT L · CIK 0001213822 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,376

F1 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-20-000552 · doc4_6734.xml · nonDerivative · entry 1

ERWIN ROBERT L · CIK 0001213822 · President

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 136,376

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-20-000520 · doc4_6713.xml · derivative · entry 3

Mullaney James P. · CIK 0001702906 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 11,250 shares

Expires 2024-02-20

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options.

F1 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-20-000520 · doc4_6713.xml · nonDerivative · entry 2

Mullaney James P. · CIK 0001702906 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-20-000520 · doc4_6713.xml · nonDerivative · entry 1

Mullaney James P. · CIK 0001702906 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-20-000401 · doc4a_6648.xml · derivative · entry 1

Isett Thomas Francis 3rd · CIK 0001773100 · Director · CEO and Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,275,000

Underlying: Common Stock · 975,000 shares

Expires 2030-04-21

F1 · security: This amendment amends the Form 4 filed on March 16, 2020 (the "Original Form 4"), which reported an option to purchase 975,000 shares of common stock of iBio, Inc. (the "Company"). Although the grant of such option was contemplated in the Employment Agreement, dated March 10, 2020, between Mr. Isett and the Company, the Original Form 4 was filed in error because the option had not yet been issued by the Company. Effective April 21, 2020, Mr. Isett and the Company entered into an Amended and Restated Employment Agreement and the Company issued an option to purchase 975,000 shares of common stock to Mr. Isett pursuant to a Stock Option Agreement, as reported in this Form 4/A.

F2 · derivative.exercise_date: Vests ratably over a 36-month period beginning on March 10, 2020 (1/36th per month) and will be deemed fully-vested upon any transaction or series of related transactions that constitutes a Change of Control Transaction (as defined in the grant agreement).

SEC source: 0001638599-20-000336 · doc4_6615.xml · derivative · entry 3

Isett Thomas Francis 3rd · CIK 0001773100 · Director · CEO and Executive Co-Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,275,000

Underlying: Common Stock · 100,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: The shares of Series C Convertible Preferred Stock were acquired by Mr. Isett in a public offering by iBio, Inc. ("iBio").

F2 · derivative.exercise_price: Each Series C Preferred Share has a stated value of $1,000 and is convertible into shares of iBio's common stock at any time and from time to time at the option of the holder at a price of $0.20 per share, subject to adjustment as provided in the Certificate of Designation of Preferences, Rights and Limitations of the Series C Convertible Preferred Stock, provided that the Series C Preferred Shares may not be converted if the holder, together with the holder's affiliates, would beneficially own over 4.99% (which may be increased up to 9.99% upon election by the holder on 61 days' notice) of iBio's outstanding common stock at the time of conversion.

F8 · kind: 100,000 shares of common stock were issued to Mr. Isett upon conversion of 20 shares of Series C Convertible Preferred Stock at a conversion price of $0.20 per share in accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series C Convertible Preferred Stock. The shares of Series C Convertible Preferred Stock were acquired by Mr. Isett in a public offering by iBio.

F4 · price: Each of Series C Preferred Share was sold together with Series A Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share and Series B Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share. Each Series C Preferred Share and accompanying Series A Warrants and Series B Warrants was sold at a combined public offering price of $1,000.

F2 · derivative.exercise_date: Each Series C Preferred Share has a stated value of $1,000 and is convertible into shares of iBio's common stock at any time and from time to time at the option of the holder at a price of $0.20 per share, subject to adjustment as provided in the Certificate of Designation of Preferences, Rights and Limitations of the Series C Convertible Preferred Stock, provided that the Series C Preferred Shares may not be converted if the holder, together with the holder's affiliates, would beneficially own over 4.99% (which may be increased up to 9.99% upon election by the holder on 61 days' notice) of iBio's outstanding common stock at the time of conversion.

F3 · derivative.expiration_date: The Series C Preferred Shares have no expiration date.

F5 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-20-000336 · doc4_6615.xml · nonDerivative · entry 1

Isett Thomas Francis 3rd · CIK 0001773100 · Director · CEO and Executive Co-Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,275,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F8 · kind: 100,000 shares of common stock were issued to Mr. Isett upon conversion of 20 shares of Series C Convertible Preferred Stock at a conversion price of $0.20 per share in accordance with the Certificate of Designation of Preferences, Rights and Limitations of the Series C Convertible Preferred Stock. The shares of Series C Convertible Preferred Stock were acquired by Mr. Isett in a public offering by iBio.

F5 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-20-000336 · doc4_6615.xml · derivative · entry 4

Isett Thomas Francis 3rd · CIK 0001773100 · Director · CEO and Executive Co-Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,275,000

Underlying: Common Stock · 78,024 shares

Expires 2026-10-29

F6 · security: The Series B Warrants were acquired by Mr. Isett in a public offering by iBio.

F9 · kind: 78,024 shares of common stock were issued to Mr. Isett upon exercise of Series B Warrants at an exercise price of $0.22 per share accordance with the terms of the Series B Warrants. The Series B Warrants were acquired by Mr. Isett in a public offering by iBio, Inc.

F7 · price: The Series B Warrants were sold together with Series C Preferred Shares and Series A Warrants in the public offering. Each of Series C Preferred Share was sold together with Series A Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share and Series B Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share. Each Series C Preferred Share and accompanying Series A Warrants and Series B Warrants was sold at a combined public offering price of $1,000.

F5 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-20-000336 · doc4_6615.xml · nonDerivative · entry 2

Isett Thomas Francis 3rd · CIK 0001773100 · Director · CEO and Executive Co-Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,275,000

F9 · kind: 78,024 shares of common stock were issued to Mr. Isett upon exercise of Series B Warrants at an exercise price of $0.22 per share accordance with the terms of the Series B Warrants. The Series B Warrants were acquired by Mr. Isett in a public offering by iBio, Inc.

F5 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-20-000306 · doc4_6597.xml · derivative · entry 2

Isett Thomas Francis 3rd · CIK 0001773100 · Director · CEO and Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,275,000

Underlying: Common Stock · 975,000 shares

Expires 2025-03-11

F6 · derivative.exercise_date: Vests ratably over a 36-month period beginning on date of grant (1/36th per month) and will be deemed fully-vested upon any transaction or series of related transactions that constitutes a Change of Control Transaction (as defined in the grant agreement).

F2 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4, on an as converted to common stock basis.

SEC source: 0001638599-20-000306 · doc4_6597.xml · derivative · entry 4

Isett Thomas Francis 3rd · CIK 0001773100 · Director · CEO and Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,275,000

Underlying: Common Stock · 21,976 shares

Expires 2026-10-29

F3 · security: The Warrants were acquired by Mr. Isett in a public offering by iBio on October 29, 2019.

F4 · kind: Exchanged pursuant to an Exchange Agreement with iBio pursuant to which Mr. Isett exchanged Series A Warrants to purchase 100,000 shares of Common Stock and Series B Warrants to purchase 21,976 shares of Common Stock in exchange for 121,976 shares of Common Stock and a promissory note in the principal amount of $26,834.

F5 · price: The Warrants were sold together with Series C Preferred Shares in a public offering on October 29, 2019. Each of Series C Preferred Share was sold together with Series A Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share and Series B Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share. Each Series C Preferred Share and accompanying Series A Warrants and Series B Warrants was sold at a combined public offering price of $1,000.

F2 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4, on an as converted to common stock basis.

SEC source: 0001638599-20-000306 · doc4_6597.xml · derivative · entry 3

Isett Thomas Francis 3rd · CIK 0001773100 · Director · CEO and Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,275,000

Underlying: Common Stock · 100,000 shares

Expires 2021-10-29

F3 · security: The Warrants were acquired by Mr. Isett in a public offering by iBio on October 29, 2019.

F4 · kind: Exchanged pursuant to an Exchange Agreement with iBio pursuant to which Mr. Isett exchanged Series A Warrants to purchase 100,000 shares of Common Stock and Series B Warrants to purchase 21,976 shares of Common Stock in exchange for 121,976 shares of Common Stock and a promissory note in the principal amount of $26,834.

F5 · price: The Warrants were sold together with Series C Preferred Shares in a public offering on October 29, 2019. Each of Series C Preferred Share was sold together with Series A Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share and Series B Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share. Each Series C Preferred Share and accompanying Series A Warrants and Series B Warrants was sold at a combined public offering price of $1,000.

F2 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4, on an as converted to common stock basis.

SEC source: 0001638599-20-000306 · doc4_6597.xml · nonDerivative · entry 1

Isett Thomas Francis 3rd · CIK 0001773100 · Director · CEO and Executive Chairman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,275,000

F1 · kind: Issued pursuant to an Exchange Agreement with iBio, Inc. ("iBio") pursuant to which Mr. Isett exchanged Series A Warrants to purchase 100,000 shares of iBio's common stock ("Common Stock") and Series B Warrants to purchase 21,976 shares of Common Stock in exchange for 121,976 shares of Common Stock and a promissory note in the principal amount of $26,834. In addition, Series B Warrants to purchase 78,024 shares of Common Stock held by Mr. Isett were amended in connection with the Exchange Agreement.

F1 · price: Issued pursuant to an Exchange Agreement with iBio, Inc. ("iBio") pursuant to which Mr. Isett exchanged Series A Warrants to purchase 100,000 shares of iBio's common stock ("Common Stock") and Series B Warrants to purchase 21,976 shares of Common Stock in exchange for 121,976 shares of Common Stock and a promissory note in the principal amount of $26,834. In addition, Series B Warrants to purchase 78,024 shares of Common Stock held by Mr. Isett were amended in connection with the Exchange Agreement.

F2 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4, on an as converted to common stock basis.

SEC source: 0001638599-19-000935 · doc4_6338.xml · derivative · entry 3

Isett Thomas Francis 3rd · CIK 0001773100 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock · 100,000 shares

Expires 2026-10-29

F8 · security: The Series B Warrants were acquired by Mr. Isett in a public offering by iBio.

F9 · price: The Series B Warrants were sold together with Series C Preferred Shares and Series A Warrants in the public offering. Each of Series C Preferred Share was sold together with Series A Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share and Series B Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share. Each Series C Preferred Share and accompanying Series A Warrants and Series B Warrants was sold at a combined public offering price of $1,000.

F5 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4, on an as converted to common stock basis.

SEC source: 0001638599-19-000935 · doc4_6338.xml · derivative · entry 2

Isett Thomas Francis 3rd · CIK 0001773100 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock · 100,000 shares

Expires 2021-10-29

F6 · security: The Series A Warrants were acquired by Mr. Isett in a public offering by iBio.

F7 · price: The Series A Warrants were sold together with Series C Preferred Shares and Series B Warrants in the public offering. Each of Series C Preferred Share was sold together with Series A Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share and Series B Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share. Each Series C Preferred Share and accompanying Series A Warrants and Series B Warrants was sold at a combined public offering price of $1,000.

F5 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4, on an as converted to common stock basis.

SEC source: 0001638599-19-000935 · doc4_6338.xml · derivative · entry 1

Isett Thomas Francis 3rd · CIK 0001773100 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Common Stock · 100,000 shares

Expires not disclosed

F1 · security: The shares of Series C Convertible Preferred Stock, $0.001 par value (the "Series C Preferred Shares"), were acquired by Mr. Isett in a public offering by iBio, Inc. ("iBio").

F2 · derivative.exercise_price: Each Series C Preferred Share has a stated value of $1,000 and is convertible into shares of iBio's common stock at any time and from time to time at the option of the holder at a price of $0.20 per share, subject to adjustment as provided in the Certificate of Designation of Preferences, Rights and Limitations of the Series C Convertible Preferred Stock, provided that the Series C Preferred Shares may not be converted if the holder, together with the holder's affiliates, would beneficially own over 4.99% (which may be increased up to 9.99% upon election by the holder on 61 days' notice) of iBio's outstanding common stock at the time of conversion.

F4 · price: Each of Series C Preferred Share was sold together with Series A Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share and Series B Warrants to purchase one share of common stock for each share of common stock issuable upon conversion of the Series C Preferred Share. Each Series C Preferred Share and accompanying Series A Warrants and Series B Warrants was sold at a combined public offering price of $1,000.

F2 · derivative.exercise_date: Each Series C Preferred Share has a stated value of $1,000 and is convertible into shares of iBio's common stock at any time and from time to time at the option of the holder at a price of $0.20 per share, subject to adjustment as provided in the Certificate of Designation of Preferences, Rights and Limitations of the Series C Convertible Preferred Stock, provided that the Series C Preferred Shares may not be converted if the holder, together with the holder's affiliates, would beneficially own over 4.99% (which may be increased up to 9.99% upon election by the holder on 61 days' notice) of iBio's outstanding common stock at the time of conversion.

F3 · derivative.expiration_date: The Series C Preferred Shares have no expiration date.

F5 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4, on an as converted to common stock basis.

SEC source: 0001638599-19-000580 · doc4_6100.xml · derivative · entry 1

GENERAL HILL (Ret) JAMES T. · CIK 0001441718 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,750

Underlying: Common Stock · 50,000 shares

Expires 2029-04-01

SEC source: 0001638599-19-000581 · doc4_6099.xml · derivative · entry 1

FLUG SEYMOUR · CIK 0001216262 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,500

Underlying: Common Stock · 50,000 shares

Expires 2029-04-01

SEC source: 0001638599-19-000583 · doc4_6097.xml · derivative · entry 1

Kay Robert · CIK 0001285612 · Director · Executive Chairman and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 357,500

Underlying: Common Stock · 50,000 shares

Expires 2029-04-01

SEC source: 0001638599-19-000582 · doc4_6098.xml · derivative · entry 1

Chang Glenn · CIK 0001384967 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,750

Underlying: Common Stock · 50,000 shares

Expires 2029-04-01

SEC source: 0001638599-19-000579 · doc4_6103.xml · derivative · entry 1

Elliott Arthur Y · CIK 0001506688 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,500

Underlying: Common Stock · 50,000 shares

Expires 2029-04-01

SEC source: 0001638599-19-000576 · doc4_6104.xml · derivative · entry 1

Isett Thomas Francis 3rd · CIK 0001773100 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires 2029-04-01

SEC source: 0001638599-19-000718 · doc4_6233.xml · derivative · entry 1

MCKEY JOHN D JR · CIK 0001120452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 94,250

Underlying: Common Stock · 50,000 shares

Expires 2029-04-01

SEC source: 0001638599-19-000719 · doc4_6232.xml · derivative · entry 1

RUSSELL PHILIP K. · CIK 0001486819 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,500

Underlying: Common Stock · 50,000 shares

Expires 2029-04-01

SEC source: 0001408408-19-000014 · kbd-ibiof4032019.xml · nonDerivative · entry 1

DART KENNETH BRYAN · CIK 0001331271 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Company

Disclosed balance after: 1

F1 · security: As of March 14, 2019, the Reporting Person indirectly owns 71.70% of an entity that holds one share of the Issuer's Preferred Stock designated as iBio CMO Preferred Tracking Stock with a par value of $0.001 per share (the "Preferred Tracking Stock").

F1 · shares: As of March 14, 2019, the Reporting Person indirectly owns 71.70% of an entity that holds one share of the Issuer's Preferred Stock designated as iBio CMO Preferred Tracking Stock with a par value of $0.001 per share (the "Preferred Tracking Stock").

F1 · price: As of March 14, 2019, the Reporting Person indirectly owns 71.70% of an entity that holds one share of the Issuer's Preferred Stock designated as iBio CMO Preferred Tracking Stock with a par value of $0.001 per share (the "Preferred Tracking Stock").

F1 · balance_after: As of March 14, 2019, the Reporting Person indirectly owns 71.70% of an entity that holds one share of the Issuer's Preferred Stock designated as iBio CMO Preferred Tracking Stock with a par value of $0.001 per share (the "Preferred Tracking Stock").

SEC source: 0001408408-20-000003 · ownership.xml · nonDerivative · entry 1

DART KENNETH BRYAN · CIK 0001331271 · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Company

Disclosed balance after: 1

F1 · shares: The amendment is filed solely to reflect the Reporting Person's ownership interest being 72.71% of an entity that holds one share of the Issuer's Preferred Stock designated as iBio CMO Preferred Tracking Stock with a par value of $0.001 per share.

F1 · price: The amendment is filed solely to reflect the Reporting Person's ownership interest being 72.71% of an entity that holds one share of the Issuer's Preferred Stock designated as iBio CMO Preferred Tracking Stock with a par value of $0.001 per share.

F1 · balance_after: The amendment is filed solely to reflect the Reporting Person's ownership interest being 72.71% of an entity that holds one share of the Issuer's Preferred Stock designated as iBio CMO Preferred Tracking Stock with a par value of $0.001 per share.

SEC source: 0001638599-19-000507 · doc4_6058.xml · derivative · entry 18

MCKEY JOHN D JR · CIK 0001120452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,250

Underlying: Common Stock · 4,500 shares

Expires 2024-02-20

F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person.

F4 · derivative.exercise_date: Fully vests on first anniversary of grant date.

F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-19-000507 · doc4_6058.xml · derivative · entry 17

MCKEY JOHN D JR · CIK 0001120452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,250

Underlying: Common Stock · 6,000 shares

Expires 2027-05-01

F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options.

F1 · derivative.exercise_date: Vested in three equal annual instalments on the anniversary of the date of grant.

F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-19-000507 · doc4_6058.xml · derivative · entry 16

MCKEY JOHN D JR · CIK 0001120452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,250

Underlying: Common Stock · 7,500 shares

Expires 2024-02-20

F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person.

F4 · derivative.exercise_date: Fully vests on first anniversary of grant date.

F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-19-000507 · doc4_6058.xml · derivative · entry 15

MCKEY JOHN D JR · CIK 0001120452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,250

Underlying: Common Stock · 10,000 shares

Expires 2025-09-04

F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options.

F1 · derivative.exercise_date: Vested in three equal annual instalments on the anniversary of the date of grant.

F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-19-000507 · doc4_6058.xml · derivative · entry 14

MCKEY JOHN D JR · CIK 0001120452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,250

Underlying: Common Stock · 4,500 shares

Expires 2024-02-20

F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person.

F4 · derivative.exercise_date: Fully vests on first anniversary of grant date.

F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-19-000507 · doc4_6058.xml · derivative · entry 13

MCKEY JOHN D JR · CIK 0001120452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,250

Underlying: Common Stock · 6,000 shares

Expires 2024-09-05

F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options.

F1 · derivative.exercise_date: Vested in three equal annual instalments on the anniversary of the date of grant.

F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-19-000507 · doc4_6058.xml · derivative · entry 12

MCKEY JOHN D JR · CIK 0001120452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,250

Underlying: Common Stock · 4,500 shares

Expires 2024-02-20

F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person.

F4 · derivative.exercise_date: Fully vests on first anniversary of grant date.

F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-19-000507 · doc4_6058.xml · derivative · entry 11

MCKEY JOHN D JR · CIK 0001120452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,250

Underlying: Common Stock · 6,000 shares

Expires 2023-07-16

F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options.

F1 · derivative.exercise_date: Vested in three equal annual instalments on the anniversary of the date of grant.

F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-19-000507 · doc4_6058.xml · derivative · entry 10

MCKEY JOHN D JR · CIK 0001120452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,250

Underlying: Common Stock · 4,500 shares

Expires 2024-02-20

F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person.

F4 · derivative.exercise_date: Fully vests on first anniversary of grant date.

F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-19-000507 · doc4_6058.xml · derivative · entry 9

MCKEY JOHN D JR · CIK 0001120452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,250

Underlying: Common Stock · 6,000 shares

Expires 2022-07-24

F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options.

F1 · derivative.exercise_date: Vested in three equal annual instalments on the anniversary of the date of grant.

F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-19-000507 · doc4_6058.xml · derivative · entry 8

MCKEY JOHN D JR · CIK 0001120452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,250

Underlying: Common Stock · 4,500 shares

Expires 2024-02-20

F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person.

F4 · derivative.exercise_date: Fully vests on first anniversary of grant date.

F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-19-000507 · doc4_6058.xml · derivative · entry 7

MCKEY JOHN D JR · CIK 0001120452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,250

Underlying: Common Stock · 6,000 shares

Expires 2021-10-21

F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options.

F1 · derivative.exercise_date: Vested in three equal annual instalments on the anniversary of the date of grant.

F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-19-000507 · doc4_6058.xml · derivative · entry 6

MCKEY JOHN D JR · CIK 0001120452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,250

Underlying: Common Stock · 2,250 shares

Expires 2024-02-20

F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person.

F4 · derivative.exercise_date: Fully vests on first anniversary of grant date.

F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-19-000507 · doc4_6058.xml · derivative · entry 5

MCKEY JOHN D JR · CIK 0001120452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,250

Underlying: Common Stock · 3,000 shares

Expires 2020-08-16

F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options.

F1 · derivative.exercise_date: Vested in three equal annual instalments on the anniversary of the date of grant.

F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-19-000507 · doc4_6058.xml · derivative · entry 4

MCKEY JOHN D JR · CIK 0001120452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,250

Underlying: Common Stock · 4,500 shares

Expires 2024-02-20

F5 · price: On 2/20/19, the issuer issued new stock options, pursuant to the issuer's option exchange program, in exchange for old stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including this option grant to the reporting person.

F4 · derivative.exercise_date: Fully vests on first anniversary of grant date.

F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.

SEC source: 0001638599-19-000507 · doc4_6058.xml · derivative · entry 3

MCKEY JOHN D JR · CIK 0001120452 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,250

Underlying: Common Stock · 6,000 shares

Expires 2019-08-10

F2 · price: On 2/20/19, the issuer canceled, pursuant to the issuer's option exchange program, old stock options in exchange for new stock options, on the basis of three new options in exchange for four old options, for all eligible option holders who elected to participate in the option exchange, including the cancelation of this option grant to the reporting person in exchange for new options.

F1 · derivative.exercise_date: Vested in three equal annual instalments on the anniversary of the date of grant.

F3 · balance_after: Reflects number of securities beneficially owned following all transactions reported on this Form 4.